Valbiotis SAS (ALVAL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Valbiotis SAS (ALVAL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12352
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Valbiotis SAS (Valbiotis) is a biotechnology company that develops novel solutions to help prevent cardiometabolic diseases, besides nutrition products. It develops solutions to prevent type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity and cardiovascular diseases. The company has three products under development based on the active ingredient TOTUM-63. They include Valedia, indicated in prediabetic stage; VAL-63 NAFLD, for the treatment of NASH; and VAL-630, for the treatment of NASH and type 2 diabetes. The company’s pipeline products also include Lipidrive for obesity and VAL–070 for dyslipidemia. The company has partnerships with academic centers to develop its products, besides financial support from the European Union. Valbiotis is headquartered in La Rochelle, France.

Valbiotis SAS (ALVAL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Valbiotis SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Valbiotis SAS, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Valbiotis Raises USD2.45 Million in Second Round Financing 10
Valbiotis Raises USD1.6 Million in Venture Financing 11
Partnerships 12
Valbiotis Enters into Agreement with Biofortis 12
Valbiotis Enters into Agreement with Catholic University of Louvain 13
Valbiotis, Blaise Pascal University and Laboratoire AME2P Enter into Research Agreement 14
Licensing Agreements 15
Valbiotis Enters into Option for Licensing Agreement with SATT Grand Centre 15
Equity Offering 16
Valbiotis Completes Underwriter Partial Exercise of Over-Allotment Option of IPO for USD13.7 Million 16
Valbiotis SAS – Key Competitors 17
Valbiotis SAS – Key Employees 18
Valbiotis SAS – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Strategy And Business Planning 20
Sep 06, 2017: VALBIOTIS Opens a New Clinical Investigation Center at the Institut Pasteur in Lille as Part of the Phase IIa study on Totum-63, the Active Ingredient of Valedia 20
Financial Announcements 21
Sep 29, 2017: VALBIOTIS: First Half of 2017 21
Corporate Communications 24
Oct 08, 2018: Valbiotis confirms its international expansion with the appointment of Murielle Cazaubiel, founder and former executive director of Biofortis Merieux Nutrisciences Europe 24
Aug 30, 2018: VALBOTIS strengthens its board of directors and announces the appointment of Pascal SIRVENT 26
Sep 20, 2017: International Pharmaceutical and Nutrition Expert Dr. Jean Zetlaoui Joins VALBIOTIS’ Supervisory Board 27
Product News 28
Dec 04, 2017: Metformin + TOTUM-63 combination: VALBIOTIS announces first preclinical data for possible use in diabetes real life practice 28
Dec 04, 2017: Metformin + TOTUM-63 Combination: VALBIOTIS Announces First Preclinical Data for Possible Use in Diabetes Real Life Practice 29
Mar 06, 2018: VALBIOTIS: LpD64 acts on alterations of the microbiota involved in the development of obesity 30
Feb 27, 2018: VALBIOTIS completes Phase I/II clinical study recruitment for VAL-070, a product to reduce a cardiovascular risk factor 31
Other Significant Developments 32
Sep 18, 2018: VALBIOTIS expands its innovation capacity with its new Discovery and Preclinical Research platform 32
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Valbiotis SAS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Valbiotis SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Valbiotis SAS, Deals By Therapy Area, 2012 to YTD 2018 8
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Valbiotis Raises USD2.45 Million in Second Round Financing 10
Valbiotis Raises USD1.6 Million in Venture Financing 11
Valbiotis Enters into Agreement with Biofortis 12
Valbiotis Enters into Agreement with Catholic University of Louvain 13
Valbiotis, Blaise Pascal University and Laboratoire AME2P Enter into Research Agreement 14
Valbiotis Enters into Option for Licensing Agreement with SATT Grand Centre 15
Valbiotis Completes Underwriter Partial Exercise of Over-Allotment Option of IPO for USD13.7 Million 16
Valbiotis SAS, Key Competitors 17
Valbiotis SAS, Key Employees 18

List of Figures
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Valbiotis SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Valbiotis SAS (ALVAL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sky Deutschland GmbH:企業の戦略・SWOT・財務情報
    Sky Deutschland GmbH - Strategy, SWOT and Corporate Finance Report Summary Sky Deutschland GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Primearth EV Energy Co Ltd:企業の戦略的SWOT分析
    Primearth EV Energy Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • The Hearst Corporation:企業の戦略的SWOT分析
    The Hearst Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Adept Technology, Inc.:企業の戦略的SWOT分析
    Adept Technology, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Aggreko Plc (AGK):企業の財務・戦略的SWOT分析
    Aggreko Plc (AGK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Northern Sun Mining Corp:企業の戦略・SWOT・財務分析
    Northern Sun Mining Corp - Strategy, SWOT and Corporate Finance Report Summary Northern Sun Mining Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • NightstaRx Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary NightstaRx Ltd (NightstaRx) a subsidiary of Nightstar Therapeutics PLC is a clinical-stage gene therapy company that engaged in developing and commercializing novel. The company also involved in providing one-time treatments for patients suffering from rare inherited retinal diseases. It pro …
  • Themis Bioscience GmbH (THISR):製薬・医療:M&Aディール及び事業提携情報
    Summary Themis Bioscience GmbH (Themis Bioscience) is a biotechnology company that develops prophylactic vaccines for emerging tropical infections. The company develops emerging and specialist indications and vaccines from preclinical to late-stage clinical development phases. It develops novel vacc …
  • Skandinaviska Enskilda Banken AB:企業のM&A・事業提携・投資動向
    Skandinaviska Enskilda Banken AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Skandinaviska Enskilda Banken AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Exosome Diagnostics Inc:企業の製品パイプライン分析
    Summary Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprise miRNA profiling, mRNA p …
  • TimberWest Forest Corporation:企業の戦略・SWOT・財務情報
    TimberWest Forest Corporation - Strategy, SWOT and Corporate Finance Report Summary TimberWest Forest Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Vodacom Group Ltd (VOD):企業の財務・戦略的SWOT分析
    Vodacom Group Ltd (VOD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Apotex, Inc.:企業の戦略・SWOT・財務情報
    Apotex, Inc. - Strategy, SWOT and Corporate Finance Report Summary Apotex, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • CG Power and Industrial Solutions Ltd (CGPOWER):電力:M&Aディール及び事業提携情報
    Summary CG Power and Industrial Solutions Ltd (CG), formerly Crompton Greaves Limited, is a provider of various solutions for the management and application of electrical energy. It carries out the design, manufacture and marketing of electrical products and services related to utilities, power gene …
  • Omnova Solutions Inc (OMN):企業の財務・戦略的SWOT分析
    Omnova Solutions Inc (OMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Haworth, Inc.:企業の戦略・SWOT・財務分析
    Haworth, Inc. - Strategy, SWOT and Corporate Finance Report Summary Haworth, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Mediclinic International Plc (MDC):企業の財務・戦略的SWOT分析
    Mediclinic International Plc (MDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Huge China Holdings Limited (428):企業の財務・戦略的SWOT分析
    Huge China Holdings Limited (428) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Fondation MEDINA-製薬・医療分野:企業M&A・提携分析
    Summary Fondation MEDINA (MEDINA) is a research organization that discovers biologically active molecules and drug candidates for unmet medical needs. The organization’s services include access to natural products libraries, drug discovery contract research with its high throughput screening platfor …
  • Smiths Group plc:戦略・SWOT・企業財務分析
    Smiths Group plc - Strategy, SWOT and Corporate Finance Report Summary Smiths Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆